NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma MajesTEC1
NCT03275285: Phase 3 - Isatuximab, Carf & Dex VS Carf And Dex In Relapse Multiple Myeloma (IKEMA)
NCT03269136: Phase 1 -PF-06863135 As Single Agent & with Immunomodulatory Agents In relapsed Myeloma
NCT03314181: Phase 2 - Venetoclax, Daratumumab and Dex (+/- Bortezomib) in RRMM Multiple Myeloma
NCT03110562 : Phase 3 - Bortezomib, Selinexor, and Dexamethasone in Patients With Myeloma (BOSTON)
NCT03301220: Phase 3: A Study of Subcutaneous Daratumumab Versus Active Monitoring in HI Risk SMM
NCT03361748 : KarMMa - Phase 2 - To Determine the Efficacy and Safety of bb2121 in refractory MM
NCT02755597: NCT02755597: Phase 3 - Venetoclax (ABT-199), Bortezomib and Dexamethasone in RRMM
NCT02963493: Phase 2 - Melphalan Flufenamide (Melflufen) With Dexamethasone in Relapsed MM (HORIZON)
NCT02773030: Phase 1/2: CC-220 Monotherapy and in Combination With Treatments in NDMM / RRMM
NCT02899052: Phase 2: Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in RRMM
NCT02990338: Phase 3 - Isatuximab, Pomalidomide & Dex VS Pom & Dex in relapsed Myeloma (ICARIA-MM)
NCT02654132 : Phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab ( ELOQUENT-3)
NCT02675452: Phase 1 - AMG 176 First in Human Trial in RRMM / Relapsed or Refractory AML
NCT02541383: Phase 3 - Bortezomib, thalidomide, dex +/-Daratumumab before & after ASCT (CASSIOPEIA)
NCT02336815 : Phase 2 - Selinexor Treatment of Refractory Myeloma (STORM)
NCT02343042: Phase 1/2 - Selinexor and Backbone Treatments of Multiple Myeloma Patients (STOMP)
NCT02561962: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma
NCT02519452: Phase 1 - Daratumumab + Recombinant Human Hyaluronidase (rHuPH20) RRMM - PAVO Study